Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript August 7, 2023
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only. After the presentation, there will be an opportunity to ask questions. I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.
Vince Anzalone: Thank you, Steven. Good afternoon, and thank you for joining us today to discuss Arrowhead’s results for its Fiscal 2023 Third Quarter Ended June 30, 2023. With us today from management are President and CEO, Dr. Chris Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our Chief Medical Officer, who will provide an update on our mid and later-stage clinical pipeline; Dr. James Hamilton, our Chief of Discovery and Translational Medicine, who will provide an update on our earlier stage programs; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. In addition, Tracy Oliver, our Chief Commercial Officer and Patrick O’Brien, our Chief Operating Officer and General Counsel, will both be available during the Q&A portion of the call.
Before we begin, I would like to remind you that, comments made during today’s call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q. I'd now like to turn the call over to Chris Anzalone, President and CEO of the company.
Chris?
Chris Anzalone: Thanks, Vince. Good afternoon, everyone and thank you for joining us today. Our industry is built on promise. Sometimes this promise can be stunning and carry with it the possibility of saving the lives of some and drastically improving life for others. Arrowhead's mission is to bring important new medicines to the people who need them and save lives and alleviate suffering where we can. While this is our guiding principle and focusing on this promise has given us purpose and the motivation to, I believe, innovate at industry-leading levels and operate at speeds not seen before, it is not the only important focus for us. Another is risk. Our industry swings in a sea of risk. We recognize that in order to succeed, we need to appreciate the great promise in front of us, but focus on all the risks between the idea and the medicine ultimately given to a patient.
We are idealists, but we are not naive. One of our most important jobs is to mitigate and decrease risk where we can. We have made great progress on this broad front since our last call, and this is how I would like to frame our discussion today. Let's begin with pulmonary. We believe we've taken an important step towards further de-risking the entire pulmonary franchise with the first chronic GLP toxicology results starting to come in. For ARO-MMP7, the no AEL or no observed adverse effect level, was the highest dose we tested in our chronic rat study. In other words, even at the highest dose tested, we are not seeing anything that is deemed adverse. The highest dose represents what we believe would be substantially greater exposure than would be applied to humans.
We are waiting for final rat data from the ARO-RAGE chronic GLP tox study, but that also is looking like the will be the highest dose we tested. We are still waiting for the nine-month monkey data in both candidates, but our experience with ARO-ENaC leads us to believe that the rat is the more sensitive species for these pulmonary tox studies. So, it is very encouraging to us that the rodent studies look so positive. This is potentially a big step forward for the platform. As you may recall, we saw lung inflammation in some of the chronic GLP tox doses for ARO-ENaC in 2021. Based on our analysis of those results, we concluded that we needed to increase the potency of our pulmonary candidates, and we clearly did that with ARO-MMB7, ARO-RAAGE, and ARO- MUC5AC.
We were optimistic that these improvements would translate into better chronic tox results, but of course, we couldn't know until the data came in. As we are now seeing preliminary data from those studies come in, we are increasingly confident that ARO-MMB7 and likely ARO-RAGE may have substantially wider tox windows than ARO-ENAC did. And I believe this represents a significant derisking event for the pulmonary franchise. We look forward to having a complete rat and monkey chronic GLP tox data for ARO-RAGE and ARO-MMB7 in coming months and expect to have chronic GLP tox data for ARO-MUK5AC next year. Encouraging preliminary chronic GLP tox data follow prior derisking events in the pulmonary franchise over the past quarter. Specifically, I believe the ARO-RAGE clinical data indicate three important things; first, the safety and tolerability reports to-date have been good and nothing surprising has emerged.
This is always a critical first step for a new platform and every new drug. Second, the activity data we have seen thus far have been impressive and showed continued dose response through the top dose level. After a single inhaled dose of 184 milligrams of ARO-RAGE, we saw up to 95% knockdown with a mean of 90% in that cohort. Not only is this a high level of target gene knockdown that was extraordinarily consistent across participants in the cohort. Each subject had a good response. This is in the same ballpark as what we now expect with optimized liver-targeted programs, and this is an important point. I think it is generally accepted that RNAi is a reliable modality to safely reduce expression of a target gene and that when Arrowhead introduces a new liver program, there is high expectation both internally and externally, that the drug candidate will reduce expression of the target protein as designed.
I am hopeful that each new data set we are approaching with -- I'm sorry, I am hopeful that with each new data set that we are approaching this expectation in pulmonary, got is a giant leap forward and an important value inflection plan. Lastly, we think the data also shows that the duration of effect with ARO-RAGE supports a dosing interval of two months or more. This is an important derisking event because it limits accumulated drug exposure, increasing our confidence that the good safety profile seen thus far may continue during treatment. It would also be a very patient-friendly dosing regimen. Derisking the pulmonary platform is important for its own sake. As we have said in the past, we see many potential drugs coming out of the franchise that could address a number of unmet medical needs and we appear to be the only company able to effectively use RNAi in the lungs.
The pulmonary franchise alone could be the basis of a large company. But it's also important as an example of how we seek to derisk our broader business. From our perspective, a one or two-drug company is a bet, not a business. From the beginning, we have sought to create a broadly diversified business to increase the number of patients we serve, but also importantly, as a hedge against the unpredictability of biology. In our industry, the risk of failure is substantial, and our mitigation strategy has been part innovation and part group force. We have sought to create a technological platform that works reliably, and then move as fast as we can to create as many well thought-out drug candidates as possible. We've built and continue to refine and expand the reach of our TRiM platform.
This is a modular, structurally simple system to one address multiple cell types, which allows our therapies to go where a disease is in a way that other RNA companies do not. Two, move rapidly from idea to the clinic, and then efficiently through mid- and late-stage clinical studies. And three, provide platform continuity and competence, which gives us an enhanced expectation of success for new candidates that we believe far exceeds that of biotech broadly. Lessons learned developing each candidate informs the development of future candidates. So our expectation of success grows stronger over time. We believe this translates to the potential for more candidates to become approved therapies than industry average. Our 2025 initiative follows this platform development and represents to some extent, the brute force component of our broader risk mitigation strategy.
We have platforms that appear to work well, so we have the responsibility to our patients and stakeholders to build as many new drugs as fast as we can. It is our goal to have 20 clinical stage or marketed products by the year 2025. Somewhat paradoxically, building such a large pipeline is part of our strategy to mitigate balance sheet risk. We are in a very expensive business and one could argue that the best way to ensure we are properly capitalized to bring drugs to market is to have a small, focused pipeline. We reject that. Rather, we believe that well thought-out drug candidates with greater than industry average chances of success can always find homes in partner companies' pipelines. As we mentioned at our Analyst Day in June, we have brought in nearly $1 billion in partnering capital over the past six years and have not raised equity capital for over 3.5 years.
In fact, GSK recently initiated a Phase IIb study of GSK4532990 formerly called ARO-HSD, for the treatment of NASH, which earned us a $30 million milestone payment. In addition, Takeda initiated the Phase III REDWOOD study of Fazirsiran being developed as a potential treatment for Alpha-1 Antitrypsin Deficiency liver disease, which are in the Arrowhead, a $40 million milestone payment. We believe that partnering is a good cornerstone of a broader financing strategy and one that our platforms are uniquely suited for because of the quality of the candidates coming out of them, and the scarcity of the companies that are skilled at generating RNAi-based therapeutics. Our partnering strategy includes existing partnerships that are maturing and therefore, listening to higher payments, new potential partnerships that could combine our platforms with a partner's target or set of targets and new partnerships on existing programs in our pipeline.
Regarding the latter on our last earnings call, I discussed that at the time we had paused the CTA filing because of some inbound interest in partnering ARO-DUX4. We continue to explore those options. However, we decided to move forward with the ARO-DUX4 CTA filing ourselves. Partnering discussions can take time, and we don't ultimately know if they will translate into license agreements. We felt it did not make sense to further delay the CTA filing in the Phase I study. While partnering continues to be a cornerstone of our financing model, we are certainly cognizant of the risk of over partnering. We believe the best way to build a lot of value quickly is to retain some wholly owned candidates and drive toward commercialization. Of course, there is substantial risk with this, of course, but over the past quarter, we believe we have taken some off the table.
We completed enrollment in the Phase III PALISADE study of ARO-APOC3 in patients with familial chylomicronemia syndrome, or FCS. This is an important milestone for Arrowhead, because it will likely be the first candidate and indication that we will seek regulatory approval for. The final study visit for the last patient in is scheduled for Q2 of 2024, so we expect to start the NDA process next year. In addition to FCS, we are currently working on the Phase 3 plans for severe hypertriglyceridemia and mixed dyslipidemia, which we will be discussing with regulators this year. Shortly after those discussions, we plan to start Phase 3 studies for those larger indications. Our other wholly-owned cardiometabolic candidates, ARO-ANG3 also had an important milestone during the quarter.
We presented data at the European Atherosclerosis Society Congress demonstrating that ARO-ANG3 achieved LDL-C reductions of 44% to 48% when added to existing standard of care treatments. These results are similar to results seen in studies of an approved monoclonal antibody targeting ANGPTL3 in patients with HOFH. These are important derisking data, as we move toward one or more Phase 3 programs, which we are currently designing. We are actively working on go-to-market strategies for multiple candidates. We expect to have four drug candidates in Phase 3 studies by the end of the year. Two of these are currently wholly-owned, ARO-APOC3 and ARO-ANG3; and third, fazirsiran, is partnered with a 50-50 profit share in the U.S., so we have retained substantial economics.
As I mentioned, we will have our first Phase 3 registrational study readout mid next year for our APOC3 -- our ARO-APOC3 program in FCS and expect an NDA soon thereafter. As we look at our pipeline, we expect additional NDA filing opportunities on a very regular basis going forward. Moving to our earlier-stage pipeline. We filed two CTAs for two new programs targeting gene expression in two different tissue types. I already mentioned ARO-DUX4 and skeletal muscle for the treatment of FSHD, and the other is ARO-SOD1 in the central nervous system for the treatment of ALS. We expect additional CTAs over the next few quarters using both the CNS and skeletal muscle platforms. Of course, these are early, but they represent important derisking events for potential CNS and skeletal muscle franchises.
As with our advances in pulmonary, these are also illustrative of our desire to expand the reach of our technology and decrease the overall risk of our business by creating value across many different channels. Lastly, before I hand the all over to Javier, I want to highlight the R&D Day that we hosted in June. During that presentation, which is still available to view on our website, we gave updates and had external KOLs, talk about some existing clinical programs in cardiometabolic and pulmonary disease and discuss what's next for us in CNS tissue, including potentially systemic delivery and delivery to adipose tissue. The R&D Day had a lot of detail. We are constantly pushing our technology forward and expanding its reach. With that overview, I'd now like to turn the call over to Dr. Javier San Martin.
Javier?
Javier San Martin : Thank you, Chris, and good afternoon, everyone. The design, planning and preparation of the late-stage studies of our cardiometabolic candidates, ARO-APOC3 and ARO-ANG3 is well underway, while making good progress towards our goal of conducting multiple and a Phase 2 meeting with regulators this year and initiated multiple Phase 3 studies late this year and early next year. We also intend to present final Phase 2 data at the American Higher Association meeting in November, pending attractant for multiple studies for both ARO-APOC3 and ARO-ANG3. Let's take a moment to review the various studies we have concluded, and then I will provide our current thinking around the Phase 3 studies, may -- how the Phase 3 study may look like for each clinical indication.
How we start with ARO-APOC3? Our investigational RNAi therapeutic being developed as a treatment for patients with mixed dyslipidemia, severe hypertriglyceridemia and familial chylomicronemia syndrome. ARO-APOC3 is designed to reduce production of Apolipoprotein C3 or APOC3, a component of triglyceride rich lipoproteins, including very low-density lipoproteins or VLDL and chylomicrons and a key regulator of triglyceride metabolism, knocking down thehepatic production of APOC3 by RNAi results in reduced VLDL synthesis and assembly, enhanced breakdown of triglyceride rich lipoproteins, and better clearance of VLDL andchylomicron remnants PILPL-dependent and independent pathway. We view ARO-APOC3 as having the potential to address many patients population with variously disorders that can lead to different clinical complications and [indiscernible].
Familial Chylomicronemia Syndrome or FCS is characterized by extremely high TG levels typically over 1,000 milligrams per deciliter and as high as 5,000 milligrams per deciliter, leading the high rates of acute pancreatitis that usually requires hospitalization and can be favored. Patients with FCS may also experience chronic abdominal pain, and they had to adhere to very strict diet with very low fat content, leading to improve their quality flat. FCS is a severe and ultra rare genetic disease that affects hundreds to a few thousand patients in the US. Severe Hypertriglyceridemia or sHTG is characterized by marked elevation in TG, typically over 500 milligrams per deciliter, which can lead to increased risk of acute pancreatitis, as well as an increased risk of cardiovascular disease.
This condition is estimated to affect several million patients in the US. Lastly, Mixed Dyslipidemia Lima is defined as a person of higher [indiscernible] cholesterol combined with teaches remnants cholesterol and low HDL. The leading profile is a major component of the risk factor for erosive cardiovascular disease. There are likely tens of millions of patients in the US with Mixed Dyslipidemia who are not a quality control with current standard of care. The studies of ARO-APOC3 that we have conducted or are planning to conduct for each population are as follows. For FCS, we are conducting the PALISADE study, which is a Phase III placebo-controlled study to evaluate the efficacy and safety of ARO-APOC3 in adults with FCS. The primary endpoint from this study is percent change from baseline in fasting TC at month 10.
Photo by Myriam Zilles on Unsplash
This study was fully enclosed in May with a total of 75 subjects distributed across 39 different sites in 18 countries who were randomized to receive 25 milligrams of ARO-APOC3, 50 milligrams of ARO-APOC3 or matching placebo once every three months. This puts us on schedule for study completion in Q2 of 2024, a data readout [indiscernible] and then NDA preparation for regulatory filings. Participants who completed randomized portion of PALISADE are also eligible to continue in an extension period, where all participants will receive ARO-APOC3. For sHTG, we are conducting the SHASTA-2 Phase II study in 229 patients randomized 3 to 1 to receive 10, 25 or 50 milligrams of ARO-APOC3, all placebo on day one and week 12. Patients with FCS were excluded from this study.
The primary endpoint is percent change from baseline fasting TG at week 24. SHASTA-2 was the study that enabled us to begin planning and design for our Phase 3 plan in SHTG patients. The data strongly support advancement into Phase 3, and we plan to present results at the American Heart Association in November. The current Phase 3 plan for SHTG includes two separate studies, which will be called SHASTA-3 and SHASTA-4 the idea behind the two studies is to have, first, a faster path to regulatory submission with the SHASTA-3 study, a double-blind, 12-month randomized control study of approximately 600 patients with teaches greater than 500 million per deciliter. We believe this study plus the large safety database from our Phase 1 and 2 study will be an appropriate package for an initial filing the SHTG indication.
The second study, SHTG-4 is decided to investigate the effect of ARO-APOC3 in a more severe population at high risk of developing pancreatitis, SHASTA-4 will include patients with TG greater than 880 milligrams per deciliter and recent history of pancreatitis. The duration of the double-blind portion of the study will be two years, and it will be powered to detect difference in the incidence of pancreatitis. This data could enable label expansion to include the indication statement of pancreatitis risk reduction, a key clinical outcome relevant to patients and reimbursement authorities. We have made a lot of progress on the planning and design of these studies and intend to have discussions with regulators this year and move forward rapidly with study initiation.
We will provide more details on the study when they begin. In the broader mixed dyslipidemia population, we're conducting the new Phase 2 study in 653 patients randomized three to one to receive 10, 25 or 50 milligrams of ARO-APOC3 or placebo on day 1 and at week 12. We included an additional cohort of participants receiving 50 milligrams on day 1 and week 24. The primary endpoint is prevention from baseline in fasting TG at week 24, with additional assessment of the changes in various lipid parameters such as LDL cholesterol, non-HDL-C, HDL, APOV, and VLDL, and other biomarkers. Similar to the SHTG study results, we believe the Phase 2 data from the newer studies strongly support advancement into a Phase 3 study, and we also plan to present these results at the American Heart.
The Phase 3 program for this population will be a cardiovascular outcome trial called CASCADE. ARO-APOC3 has demonstrated positive effect on several liquid parameters that represent residual risk factor for arteriosclerosis cardiovascular disease even after LDL is well controlled. The CASCADE study will select the patient population with high risk driven by the high TGs, remnant cholesterol, and low HDL, all of which are effectively addressed by ARO-APOC3. The study will be designed in collaboration with an academic research organization, or ARO, who are working on all aspects of the study design, including selection of the patient population, understanding and modeling background events rates, the potential effect size, and with that information we'll define the sample size and duration of exposure to be able to detect a clinically meaningful reduction in cardiovascular events.
For a finalized agreement with the selected CRO and ARO to help us conduct this important study. We are scheduled to engage with regulators later this year and plan to initiate the PALISADE study in 2024. Our strategy for ARO-APOC3 is to progressively study in larger and longer studies to potentially bring it to very high prevalence disease population that currently do not have adequate options. Our strategy for ARO-ANG3 is more focused on smaller well-defined population, ARO-ANG3 is being developed as a treatment for Homozygous Familial Hypercholesterolemia or HFH, and potentially in the future success of Heterozygous Familial Hypercholesterolemia or heFH. Phase II program for ARO-ANG3 involved two studies, the ARCHES-2 Phase II study in 204 patients with Mixed Dyslipidemia and the GATEWAY Study in 18 patients with HoFH.
Interim data from the GATEWAY Study was presented at the 91st European Atherosclerosis Society Congress in May of 2023. At study week 20, administration of 200 milligrams or 300 milligrams ARO-ANG3 on day one and day four led to mean reductions in LDL cholesterol of 48.1% and 44%, respectively. These reductions were achieved on top of continuous standard of care, including statins, ezetimibe, PCSK9 inhibitors, and apheresis. These results were on par with an approval monoclonal antibody that also target ANGPTL3, ARO-ANG3 has a much more convenient and patient-friendly dosing regimen of one subcutaneous injection every three months versus the antibody, which requires an intravenous infusion once a month. While currently working on the Phase III study design and plan for ARO-ANG3 HoFH and assessing potential other population for future studies.
I spoke in a bit more detail on both ARO-APOC3 and ARO-ANG3 during our R&D day in June. I recommend you view the archived webcast or presentation slides on our website, if you want more background on the biology of the target, some of the clinical data, the rationale for our belief in their potential and more specific information about our plans for clinical development. The other late-stage program we're working on with our partner, Takeda, is fazirsiran for the treatment of AATD liver disease. In June, update the Phase II clinical data from the SEQUOIA study were presented at EASL Congress 2023 and an oral presentation. The clinical results from the Phase II SEQUOIA study of fazirsiran were clear and compelling. Fazirsiran treatment demonstrated substantial effect on several key marker of liver disease.
Takeda has taken the lead in conducting the e Phase III REDWOOD clinical study. It is designed to enroll 160 adult patients with F2 to F4 fibrosis. The primary endpoint of the study is to decrease from baseline of at least one stage at week 106 in patients with F2 and F3 fibrosis. Takeda is doing an outstanding job at bringing global sites online for the REDWOOD study and enrolling patients efficiency. Additional information on the REDWOOD study can be found at TheRedwoodLiverStudy.com. I will now turn the call over to Dr. James Hamilton, James?
James Hamilton: Thank you, Javier. Our pipeline of early-stage clinical candidates now includes eight programs addressing various diseases with gene expression in four tissue types, including liver, lung and now muscle and CNS. Of these eight programs, most are wholly-owned and in our core areas of focus; they are in pulmonary, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, in cardiometabolic ARO-PNPLA3, in neuromuscular ARO-DUX4 and ARO-SOD1, and we also have ARO-C3 for complement-mediated diseases and HZN 457 partnered with Horizon for Gal. In addition, we have many undisclosed preclinical programs that should continue to feed our pipeline for years to come. We are increasingly looking for opportunities to focus around core areas and we are fortunate that our platform provides us with so many opportunities.
Our discovery and clinical development teams continue to be highly productive and efficient. One main benefit of drug development based on a proprietary technology platform is that it allows us to apply learnings from prior programs to each new program. This makes us faster, more precise, and I believe, yields drug candidates with a higher probability of success. The TRiM platform has given us that advantage for liver-directed programs for a few years now. We believe we are now in a period where those same advantages exist for lung-directed programs and we have the potential to get there over the next couple of years for muscle and CNS. We held a very comprehensive R&D Day during the quarter, so I'm not going to review all of Arrowhead's discovery and early development programs.
I'd like to focus on some important potentially derisking data from our ARO-RAGE program. ARO-RAGE is our RNAi therapeutic candidate designed to reduce expression of the receptor for advanced glycation end products for RAGE as a potential treatment for inflammatory pulmonary diseases such as asthma. We are currently conducting a Phase 1/2a clinical trial in normal healthy volunteers and in patients with mild to moderate asthma. We have also recently filed an amendment to add a cohort of asthma patients with high baseline levels of fractional exhaled nitric oxide or pheno which is a biomarker for the degree of IL-13-driven type 2 inflammation in the lung. Let's talk briefly about what data we generated and reported at the R&D Day. First, with respect to safety and tolerability, to-date, there have been no reported serious or severe adverse events, no study withdraws or drug discontinuations due to adverse events, and safety labs have shown no pattern of adverse changes.
There have also been no change -- has also been no change in the pattern of airway immune cells and all chest x-rays have been read as normal. These encouraging results have also been generally consistent in the ARO-MMP7 and ARO-MUC5AC programs. With respect to activity, the results to-date, especially, at the highest dose level, have exceeded our estimates and really represent a best case scenario for target engagement. We are measuring soluble RAGE protein or sRAGE and serum after multiple doses in both healthy volunteers and in patients and in BALF after a single dose in healthy volunteers and after multi doses -- multiple doses at the top dose level. The mean maximum reduction in sRAGE at the 92 milligram dose level after two doses on days one and 29 was 80% with a maximum reduction of 90%, with a long duration of effect that supports every other month dosing.
At the highest dose of 184 milligrams, we achieved a similar result after just a single dose, with mean sRAGE reduction of up to 76% and maximal reduction of 91%. We also observed a continued dose response in valve with a single inhaled dose of 184 milligrams, achieving mean reduction up 90% and maximal reduction of 95%. We are still collecting data that we intend to report on later this year, including presentations at the European Respiratory Society International Congress in September. We believe this is the first compelling clinical evidence of gene target silencing in the lung using siRNA. We also believe that these clinical results have a good chance of being predictive of clinical results in other pulmonary programs, including ARO-MUC5AC and ARO-MMP7 and additional undisclosed preclinical programs.
And lastly, on RAGE, what data are we generating over the coming months, we will have the chronic monkey GLP toxicology results before the end of the year, which will be needed prior to Phase 2 initiation. We will be getting additional longer-term follow-up and multiple dose data at the highest doses in healthy volunteers and in patients later this year and into next year. Lastly, we will be getting data from the high FeNO cohorts, which is designed to assess if RAGE knockdown leads to an IL-13 specific anti-inflammatory effect. This study is not long enough or large enough to expect an efficacy signal, but signals of inflammatory pathway inhibition after short course of exposure would be a welcome result. We expect these data in 2024. I also want to provide an update on our earliest clinical candidates.
During the last quarter, we filed CTAs for our first muscle and CNS candidates, ARO-DUX4 and ARO-SOD1, respectively. ARO-DUX4 is the first clinical candidate utilizing the TRiM platform to target disease-associated genes and skeletal muscle. ARO-DUX4 is an investigational RNAi therapeutic designed to reduce expression of the gene that encodes the human double homeobox 4 or DUX4 protein as a potential treatment for facioscapulohumeral muscular dystrophy, or FSHD. Pending regulatory clearance, we intend to proceed with a Phase 1/2a dose-escalating study to evaluate ARO-DUX4 in adult patients with FSHD type 1. The study is designed to enroll up to 52 patients. The other CTA filed during the quarter was for ARO-SOD1, the first therapeutic candidate designed for delivery to the CNS, again, leveraging the TRiM platform.
ARO-SOD1 is designed to reduce expression of superoxide dismutase 1, or SOD1 in CNS as a potential treatment for patients with amyotrophic lateral sclerosis, or ALS caused by SOD1 mutations. Pending regulatory clearance, we intend to proceed with a Phase 1 dose escalating study to evaluate ARO-SOD1 in adult patients with ALS harboring a SOD1 mutation, which is considered to be causative of ALS. The study is designed to enroll up to 24 patients. I will now turn the call over to Ken Myszkowski. Ken?
Ken Myszkowski : Thank you, James, and good afternoon, everyone. As we reported today our net loss for the quarter ended June 30, 2023, was $102.9 million or $0.96 per share based on 107 million fully diluted weighted average shares outstanding. This compares with a net loss of $72 million, or $0.68 per share based on 105.8 million fully diluted weighted average shares outstanding for the quarter ended June 30, 2022. Revenue for the quarter ended June 30, 2023, was $15.8 million compared to $32.4 million for the quarter ended June 30, 2022. Revenue in the current period primarily relates to our collaboration agreement with Takeda. Revenue is recognized as we complete our performance obligations, which include managing the ongoing AAT Phase 2 clinical trials for Takeda.
There remains $17 million of revenue to be recognized associated with the Takeda collaboration, which we anticipate will be recognized over the next year. Total operating expenses for the quarter ended June 30, 2023, were $118.5 million compared with $105.3 million for the quarter ended June 30, 2022. The key drivers of this change were increased candidate costs, partially offset by lower stock compensation expense. The increased candidate costs were primarily due to the progression of the company's pipeline of candidates into the -- into and through clinical trials, which resulted in higher outsourced clinical trial, toxicity study and manufacturing costs. Net cash used in operating activities during the three months ended June 30, 2023, was $21.4 million compared with net cash used in operating activities of $68.9 million for the three months ended June 30, 2022.
We expect our operating cash burn to be $80 million to $90 million next quarter. We expect to spend between $160 million and $180 million over the next three quarters to complete our GMP manufacturing facility and related laboratories in Verona, Wisconsin. Turning to our balance sheet. Our cash and investments totaled $494.5 million at June 30, 2023, compared to $482.3 million at September 30, 2022. The increase in our cash and investments was primarily related to the $250 million payment from the royalty -- from Royalty Pharma as well as other licensing cash inflows offset by our operating cash burn, along with continuing capital projects. Our common shares outstanding at June 30, 2023, were $107.1 million. With that brief overview, I will now turn the call back to Chris.
Chris Anzalone: Thanks, Ken. We are well on our way to reaching our 2025 goal to grow our pipeline of RNAi therapeutics to a total of 20 clinical stage or marketed product from the year 2025. However, pipeline expansion is just a means to an end. The ultimate goal and the reason we continue to invest in expanding our platform, discovering new candidates, advancing our clinical programs, and streamlining the drug manufacturing process is that it allows us to get important new medicines to patients in need as quickly and efficiently as possible. Doing this will also create a sustainable business and provide a steady stream of commercial revenue, which we now have a better line of sight on and a plan that we are executing to get there. Thank you for joining us today, and I would now like to open the call to your questions. Operator?
See also 16 Highest-Paying Programming Languages in USA and 15 Best Gold Mining Stocks To Buy Now.
To continue reading the Q&A session, please click here.
